Condition: Diffuse Large B-cell Lymphoma With no Other Specification · Sponsor: Emercell SAS
The goal of this clinical trial is to learn the safety of OT-C001 and decide a good dose in treating relapsed or refractory diffuse large B-cell lymphoma patients. It will also learn about the preliminary activity of OT-C001. Participants will: Receive a short course of chemotherapy before OT-C001 treatment. During the study treatment, participants will recieve weekly dose of OT-C001 for 3 or 6 weeks. During the study period, participants will also receive another two drugs, rituximab and IL-2, to support OT-C001 treatment. Participants need to visit the clinic or may be hospitalized according to the study plan.
This description comes directly from the study's public registry record.
Erica Wang · 886 921 865 855 · e.wang@emercell.com
Bruno Piccolella · +33 6 12 97 73 68 · bruno.piccolella@onward-therapeutics.com
Always discuss trial participation with your own doctor first.
| Saint-Eloi Hospital | Montpellier, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07044050